Key result
Elevated troponin I is linked to ~3-fold higher mortality in hospitalized COVID-19 patients.
Why the study?
The degree of myocardial injury, reflected by troponin elevation, and associated outcomes among US hospitalized patients with COVID-19 were unknown.
Cohort (n=2,736)
Yes
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“It is not all that surprising that cardiac injury is common among patients with COVID-19 and that it tracks with disease severity. Most of the troponin elevations seen in the COVID-19 setting come in at lower than what's typically seen with acute MI. The possibility of myocarditis as an explanation is one potential; some clear cases of COVID-19 myocarditis have been reported, however not all injury may be blamed on myocarditis.”
“I think that the finding in terms of [cardiac injury's] relationship to mortality is striking.”
“It's kind of scary, actually, how much the risk goes up with elevated troponin.”
Describes myocardial injury effects in hospitalized COVID-19 patients, indicating increased mortality risk.
Background The degree of myocardial injury, as reflected by troponin elevation, and associated outcomes among U.S. hospitalized patients with coronavirus disease-2019 (COVID-19) are unknown. Objectives The purpose of this study was to describe the degree of myocardial injury and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19. Methods Patients with COVID-19 admitted to 1 of 5 Mount Sinai Health System hospitals in New York City between February 27, 2020, and April 12, 2020, with troponin-I (normal value <0.03 ng/ml) measured within 24 h of admission were included (n = 2,736). Demographics, medical histories, admission laboratory results, and outcomes were captured from the hospitals’ electronic health records. Results The median age was 66.4 years, with 59.6% men. Cardiovascular disease (CVD), including coronary artery disease, atrial fibrillation, and heart failure, was more prevalent in patients with higher troponin concentrations, as were hypertension and diabetes. A total of 506 (18.5%) patients died during hospitalization. In all, 985 (36%) patients had elevated troponin concentrations. After adjusting for disease severity and relevant clinical factors, even small amounts of myocardial injury (e.g., troponin I >0.03 to 0.09 ng/ml; n = 455; 16.6%) were significantly associated with death (adjusted hazard ratio: 1.75; 95% CI: 1.37 to 2.24; p < 0.001) while greater amounts (e.g., troponin I >0.09 ng/dl; n = 530; 19.4%) were significantly associated with higher risk (adjusted HR: 3.03; 95% CI: 2.42 to 3.80; p < 0.001). Conclusions Myocardial injury is prevalent among patients hospitalized with COVID-19; however, troponin concentrations were generally present at low levels. Patients with CVD are more likely to have myocardial injury than patients without CVD. Troponin elevation among patients hospitalized with COVID-19 is associated with higher risk of mortality.
No takes yet. Share an insight, caveat, or question.
Lala et al. (2020) conducted a cohort in COVID-19 (n=2,736). Elevated troponin I (>0.09 ng/ml) vs. Normal troponin I (0.00 to 0.03 ng/ml) was evaluated on Mortality (HR 3.03, 95% CI 2.42 to 3.80, p=<0.001). Elevated troponin I was associated with a higher risk of mortality compared to normal troponin levels in patients hospitalized with COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: